Articles related to OFF-LABEL USE

Despite the potential benefits of ketamine in treating a range of neurological and psychiatric disorders, the FDA has issued warnings about the potential risks associated with its use, emphasizing the need for careful prescription and clinical oversight.

As we navigate this new era of oncology care, it’s important to remember that only 38% of studies combining chemotherapy with a targeted treatment administered both drugs at full dose. This underscores the need for careful dose adjustments when combining different classes of drugs.

The recent study on topiramate’s potential role in PTSD treatment has shown that three times as many patients taking topiramate saw their PTSD symptoms decrease below the clinical threshold compared to those on placebo.

This observational study compared IV ketamine (47) to IN esketamine (15) in 62 adults suffering treatment-resistant depression. Response was measured using the QIDS-SR tool. The results? The two formulations were comparable in terms of change between baseline and endpoint QIDS-SR and response rates. However, IV ketamine generated benefits with fewer treatments.

To sum up the reasons you should use caution: Quetiapine has a variety of effects, including sedation, influencing a number of central nervous system receptors. Quetiapine should only be used to treat insomnia in patients who also have co-occurring mood or schizophrenia spectrum disorders. Quetiapine is less frequently linked to extrapyramidal side effects and dystonia than many other antipsychotic medications, but it is more frequently linked to weight gain, metabolic syndrome, and QTc prolongation. Prior to beginning treatment and then on a frequent basis thereafter, measurements of body mass index, weight, blood pressure, fasting glucose, and lipid levels should be made, even at modest doses. Despite not producing euphoria, quetiapine is frequently misused to amplify or lessen the negative effects of illegal substances. For older patients, quetiapine has additional dangers.

Because this GLP-1 agonist is known to reduce food intake, physicians have been prescribing tirzepatide off-label for weight loss for years. But unlike other drugs in its class, tirzepatide targets GLP-1 and GIP receptors.